Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGENASDAQ:ARWRNASDAQ:CGEMNASDAQ:IRON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$32.32-7.6%$37.21$29.10▼$63.50$1.46B1.72491,236 shs1.08 million shsARWRArrowhead Pharmaceuticals$10.68-11.4%$17.31$10.66▼$30.41$1.47B0.921.36 million shs2.57 million shsCGEMCullinan Therapeutics$7.41-1.1%$9.02$7.11▼$30.19$438.26M-0.05656,014 shs600,301 shsIRONDisc Medicine$41.22-9.9%$53.45$25.64▼$68.73$1.42B0.73336,577 shs773,882 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-7.63%-18.63%+2.83%-32.34%-46.13%ARWRArrowhead Pharmaceuticals-11.44%-22.72%-38.44%-46.03%-59.67%CGEMCullinan Therapeutics-1.07%-7.61%-12.10%-41.56%-56.92%IRONDisc Medicine-9.94%-21.28%-27.58%-35.41%+35.15%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics1.9228 of 5 stars3.50.00.00.02.64.20.0ARWRArrowhead Pharmaceuticals3.0523 of 5 stars3.31.00.03.41.62.50.0CGEMCullinan Therapeutics1.9483 of 5 stars3.50.00.00.03.12.50.6IRONDisc Medicine3.0572 of 5 stars4.52.00.00.03.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$92.17185.17% UpsideARWRArrowhead Pharmaceuticals 2.60Moderate Buy$41.44288.06% UpsideCGEMCullinan Therapeutics 3.00Buy$32.86343.42% UpsideIRONDisc Medicine 3.09Buy$93.80127.56% UpsideCurrent Analyst Ratings BreakdownLatest CGEM, ARWR, IRON, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/13/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$95.003/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.003/7/2025CGEMCullinan TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$38.00 ➝ $35.003/7/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$85.003/3/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.003/3/2025IRONDisc MedicineScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$73.00 ➝ $75.002/28/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.002/27/2025IRONDisc MedicineTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy2/14/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $38.002/12/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$7.50 per shareN/AARWRArrowhead Pharmaceuticals$2.50M586.62N/AN/A$1.54 per share6.94CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.61 per shareN/AIRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$83.99M-$3.29N/AN/AN/AN/A-21.81%-20.94%5/12/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$5.17N/AN/AN/AN/A-236.60%-64.09%5/8/2025 (Estimated)CGEMCullinan Therapeutics-$153.16M-$3.03N/AN/AN/AN/A-26.54%-25.32%5/13/2025 (Estimated)IRONDisc Medicine-$76.43M-$3.99N/AN/AN/AN/A-25.24%-23.96%5/8/2025 (Estimated)Latest CGEM, ARWR, IRON, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024APGEApogee Therapeutics-$0.94-$1.19-$0.25-$1.19N/AN/A2/27/2025Q4 2024CGEMCullinan Therapeutics-$0.75-$0.73+$0.02-$0.73N/AN/A2/27/2025Q4 2024IRONDisc Medicine-$1.06-$0.98+$0.08-$0.98N/AN/A2/10/2025Q1 2025ARWRArrowhead Pharmaceuticals-$0.42-$1.39-$0.97-$1.39$19.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3916.39ARWRArrowhead Pharmaceuticals7.276.096.09CGEMCullinan TherapeuticsN/A24.4624.46IRONDisc MedicineN/A19.3619.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%ARWRArrowhead Pharmaceuticals62.61%CGEMCullinan Therapeutics86.31%IRONDisc Medicine83.70%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics36.10%ARWRArrowhead Pharmaceuticals4.30%CGEMCullinan Therapeutics6.07%IRONDisc Medicine4.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9145.03 million28.77 millionOptionableARWRArrowhead Pharmaceuticals400137.32 million120.68 millionOptionableCGEMCullinan Therapeutics3058.51 million54.69 millionOptionableIRONDisc Medicine3034.57 million28.50 millionNot OptionableCGEM, ARWR, IRON, and APGE HeadlinesRecent News About These CompaniesPictet Asset Management Holding SA Decreases Stock Position in Disc Medicine, Inc. (NASDAQ:IRON)April 4 at 3:55 AM | marketbeat.com4,875 Shares in Disc Medicine, Inc. (NASDAQ:IRON) Purchased by Virtu Financial LLCMarch 29, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Director Sells $310,483.18 in StockMarch 27, 2025 | marketbeat.comIs Disc Medicine, Inc. (NASDAQ:IRON) the Best Small Cap Stock to Buy Before They Explode?March 27, 2025 | msn.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells 5,738 Shares of StockMarch 27, 2025 | insidertrades.comRaymond James Financial Inc. Purchases New Position in Disc Medicine, Inc. (NASDAQ:IRON)March 25, 2025 | marketbeat.comWith 65% ownership, Disc Medicine, Inc. (NASDAQ:IRON) boasts of strong institutional backingMarch 23, 2025 | uk.finance.yahoo.comDisc Medicine, Inc. (NASDAQ:IRON) Director Sells $540,594.00 in StockMarch 22, 2025 | marketbeat.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells 39,656 Shares of StockMarch 22, 2025 | marketbeat.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells 10,011 Shares of StockMarch 22, 2025 | insidertrades.comVictoria’s Secret, Bitdeer, and More Stocks See Activist ActionMarch 21, 2025 | msn.comDisc Medicine, Inc. (NASDAQ:IRON) Given Consensus Recommendation of "Buy" by AnalystsMarch 20, 2025 | marketbeat.comCantor Fitzgerald Raises Disc Medicine (NASDAQ:IRON) Price Target to $132.00March 19, 2025 | marketbeat.comDisc Medicine (IRON) Gets a Buy from Cantor FitzgeraldMarch 19, 2025 | markets.businessinsider.comDisc Medicine price target raised to $132 from $99 at Cantor FitzgeraldMarch 18, 2025 | msn.comDisc Medicine (NASDAQ:IRON) Shares Down 3% - Here's What HappenedMarch 15, 2025 | marketbeat.comAll You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to BuyMarch 14, 2025 | zacks.comDisc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya Sells 83,182 SharesMarch 13, 2025 | marketbeat.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells 202,146 Shares of StockMarch 13, 2025 | marketbeat.comMona Ashiya Sells 83,182 Shares of Disc Medicine, Inc. (NASDAQ:IRON) StockMarch 13, 2025 | insidertrades.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Bought by Victory Capital Management Inc.March 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Stocks With Ironclad Balance Sheets for Long-Term StabilityBy Leo Miller | March 13, 2025View 3 Stocks With Ironclad Balance Sheets for Long-Term StabilityCan SoundHound AI Double? What the Fundamentals and Deals RevealBy Gabriel Osorio-Mazilli | March 25, 2025View Can SoundHound AI Double? What the Fundamentals and Deals RevealCGEM, ARWR, IRON, and APGE Company DescriptionsApogee Therapeutics NASDAQ:APGE$32.32 -2.67 (-7.63%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$32.26 -0.05 (-0.17%) As of 04/4/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Arrowhead Pharmaceuticals NASDAQ:ARWR$10.68 -1.38 (-11.44%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$10.94 +0.26 (+2.43%) As of 04/4/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Cullinan Therapeutics NASDAQ:CGEM$7.41 -0.08 (-1.07%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$7.42 +0.01 (+0.13%) As of 04/4/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Disc Medicine NASDAQ:IRON$41.22 -4.55 (-9.94%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$41.23 +0.01 (+0.02%) As of 04/4/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
